Nerve stimulation for treatment of diseases and disorders
View Patent ↗Methods are presented for treating a subject having a disease or disorder comprising stimulating a vagus nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific vagus neurogram in an amount and manner effective to treat the disease or disorder in a subject.
1 . A method of stimulating a vagus nerve of a first subject comprising stimulating the vagus nerve of the first subject using an electrical stimulus derived from a vagus neural signal previously obtained from a second subject,
wherein the vagus neural signal previously obtained from the second subject comprises compound action potentials that have a frequency that is greater than three times the frequency of compound action potentials during the second subject's baseline vagus nerve activity, and
wherein the vagus neural signal previously obtained from the second subject was previously generated in response to a specific disease, condition, endogenous mediator or pharmacologic agent.
2 . The method of claim 1 , wherein the first subject has a disease or disorder selected from a group consisting of one or more of inflammation, type 1 diabetes, type 2 diabetes, metabolic syndrome, insulin resistance, glucose intolerance, hyperglycemia, hypoglycemia, trauma, bleeding, hemorrhagic shock, ischemia-reperfusion injury, nausea, vomiting, cancer, prostate cancer, arthritis, rheumatoid arthritis, sepsis, endotoxemia, colitis, pancreatitis, inflammatory bowel disease, Crohn's Disease, fever, anorexia, pain, swelling, kidney failure, liver disease, hypothyroidism, a host response to infection, an immune response, and a disease or disorder in which it is desirable to change the activity or level of a cytokine.
3 . The method of claim 1 , wherein the vagus neural signal previously obtained from the second subject was previously generated in response to administration of glucagon, glucose, insulin, cortisol, dexamethasone or a cytokine to the second subject.
4 . The method of claim 1 , wherein the vagus neural signal previously obtained from the second subject was previously generated in response to a hypoglycemic or hyperglycemic state of the second subject.
5 . The method of claim 1 , wherein the first subject is a human subject or a veterinary subject.
6 . The method of claim 1 , wherein the second subject is a human subject or an animal model of a disease or disorder.
7 . A method of stimulating a vagus nerve of a first subject comprising stimulating the vagus nerve of the first subject using an electrical stimulus derived from a vagus neural signal previously obtained from a second subject;
wherein the vagus neural signal previously obtained from the second subject comprises compound action potentials that have a frequency that is greater than three times the frequency of compound action potentials during the second subject's baseline vagus nerve activity;
wherein the first subject has a disease or disorder selected from a group consisting of elevated blood glucose levels, decreased blood glucose levels and inflammation; and
wherein blood glucose levels are decreased in the first subject by stimulating the vagus nerve of the first subject using an electrical stimulus derived from a hypoglycemia-specific, insulin-specific or cortisol-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to decrease blood glucose levels in a subject, or
wherein blood glucose levels are increased in the first subject by stimulating the vagus nerve of the first subject using an electrical stimulus derived from a hyperglycemia-specific or glucose-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to increase blood glucose levels in a subject, or
wherein inflammation is treated in the first subject by stimulating the vagus nerve of the first subject with an electrical stimulus derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to reduce a sign or symptom of inflammation in a subject.
8 . The method of claim 7 , wherein the first subject has elevated blood glucose levels, and wherein blood glucose levels are decreased in the first subject by stimulating the vagus nerve of the first subject using an electrical stimulus derived from a hypoglycemia-specific, insulin-specific or cortisol-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to decrease blood glucose levels in a subject.
9 . The method of claim 8 , wherein the first subject has one or more of diabetes mellitus type 1, diabetes mellitus type 2, metabolic syndrome, glucose intolerance, insulin resistance or hyperglycemia.
10 . The method of claim 7 , wherein the first subject has decreased blood glucose levels, and wherein blood glucose levels are increased in the first subject by stimulating the vagus nerve of the first subject using an electrical stimulus derived from a hyperglycemia-specific or glucose-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to increase blood glucose levels in a subject.
11 . The method of claim 10 , wherein the first subject has one or more of hypoglycemia, kidney failure, liver disease or hypothyroidism.
12 . The method of claim 7 , wherein the first subject has inflammation, and wherein inflammation is treated in the first subject by stimulating the vagus nerve of the first subject with an electrical stimulus derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram previously obtained from the vagus nerve of the second subject in an amount and manner effective to reduce a sign or symptom of inflammation in a subject.
13 . The method of claim 12 , wherein an anti-inflammatory cytokine is selected from a group consisting of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-13 (IL-13) and interleukin-35 (IL-35).
14 . The method of claim 12 , wherein the first subject has one or more of rheumatoid arthritis, colitis, inflammatory bowel disease, Crohn's Disease, or an infection.
15 . The method of claim 7 , wherein the first subject is a human subject or a veterinary subject.
16 . The method of claim 7 , wherein the second subject is a human subject or an animal model of a disease or disorder.